Janssen Pharmaceuticals, Inc.
A single plant registered with the FDA to make drugs for the US market. Below is where it is and the drugs whose FDA labels list this site as performing a manufacturing step — so if this plant has a problem, these are the products that could be affected.
- Country
- United States
- Registered address
- PO Box 200 1125 Trenton Harbourton Rd, Titusville, New Jersey (NJ) 08560-1499, United States (USA)
- Operations here
- analysis
- FDA identifiers
- FEI 2242843 · DUNS 063137772
FDA inspection history
Outcomes of closed FDA inspections at this site (drug and biologic program areas).
- NAIDrug Quality Assurance2025-08-14
- VAIBioresearch Monitoring2024-09-27
- NAIBioresearch Monitoring2020-09-28
- NAIDrug Quality Assurance2020-09-14
- NAIDrug Quality Assurance2015-04-22
- NAIBioresearch Monitoring2013-12-12
- NAIDrug Quality Assurance2012-06-28
- NAIDrug Quality Assurance2011-06-01
- NAIDrug Quality Assurance2009-04-09
Drugs this plant is listed as making
5 distinct drugs across 28 products name this site in their FDA label.
- canagliflozin and metformin hydrochlorideJanssen Pharmaceuticals, Inc.
- darunavirJanssen Products LP
- etravirineJanssen Products LP
- Methylphenidate hydrochloridein shortageJanssen Pharmaceuticals, Inc.
- paliperidone palmitateJanssen Pharmaceuticals, Inc
Sources:the establishment's name, address, and country from FDA's Drug Establishments Current Registration Site (DECRS); the drug-to-facility links from DailyMed SPL drug labels, matched by the facility's DUNS number; inspection outcomes from the FDA Data Dashboard, matched by FEI; shortage status from FDA's drug shortage database. More on how this is built. Educational only.